Fever News and Research

RSS

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Viewpoints: Romney and 'Obamneycare'; 'fundamental constitutional flaws'; leading vs. following in Md.

Hence the young campaign's most unfortunate new coinage, courtesy of Tim Pawlenty: "Obamneycare." That's the word Pawlenty used Sunday to describe President Obama's health-care law, which borrowed ideas from the reform package Romney devised and implemented when he was governor of Massachusetts. Obamacare plus Romneycare equals . . . Okay, we get it, we get it.

15 Jun 2011

Dengue virus circulating between monkeys, mosquitoes could emerge to cause human outbreaks

More than a thousand years ago, somewhere in Southeast Asia, a fateful meeting occurred between a mosquito-borne virus that infected mainly monkeys and a large, susceptible group of humans.

14 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.

10 Jun 2011

Drop in flu vaccination rates alarms health authorities

According to latest figures the number of young children vaccinated against the flu in WA this year has plummeted almost 80 per cent. This is concerning for health officials who believe that parents have been scared off by last year's spate of seizures after the jabs.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Biogen Idec announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

7 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

ITI receives FDA clearance for new Q fever assay kit

This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.

7 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

FDA accepts Sunovion ciclesonide HFA nasal aerosol NDA for review

Sunovion Pharmaceuticals Inc. today announced that the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation has been accepted by the U.S. Food and Drug Administration.

6 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Fever News and Research

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Viewpoints: Romney and 'Obamneycare'; 'fundamental constitutional flaws'; leading vs. following in Md.

Dengue virus circulating between monkeys, mosquitoes could emerge to cause human outbreaks

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

Drop in flu vaccination rates alarms health authorities

Millennium reports results from two VELCADE based combination studies against multiple myeloma

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

ITI receives FDA clearance for new Q fever assay kit

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

FDA accepts Sunovion ciclesonide HFA nasal aerosol NDA for review

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News